Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist

被引:35
|
作者
Yu, Pengzhan
Zheng, Chunyang
Chen, Jing
Zhang, Guifeng
Liu, Yongdong
Suo, Xiaoyan
Zhang, Guicai
Su, Zhiguo [1 ]
机构
[1] Chinese Acad Sci, Inst Proc Engn, Natl Key Lab Biochem Engn, Beijing 100080, Peoples R China
[2] Chinese Acad Sci, Grad Univ, Beijing 100039, Peoples R China
[3] Beijing Baiao Pharmaceut Co Ltd, Beijing 102200, Peoples R China
基金
中国国家自然科学基金;
关键词
interleukin-1 receptor antagonist; PEGylation; binding activities to the receptors;
D O I
10.1016/j.bmc.2007.05.061
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although PEGylation is a potential approach to prolong the half-lives and reduce the dosing frequency of therapeutic proteins, conjugation behaviors of polymer have pivotal effects on the remaining bioactivities of the derivatives. In this study, the PEGylation strategy of recombinant human interleukin-1 receptor antagonist was investigated. The random conjugation of polyethylene glycol to amino groups on the protein resulted in a severe loss of activity and only retained 9.8% of the activity. In contrast, the PEGylation at the thiol groups had moderate effects on the bioactivity of protein and 40% of activity was conserved. The results suggested that the thiol-target PEGylation was more beneficial for IL-1ra. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5396 / 5405
页数:10
相关论文
共 50 条
  • [1] Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration
    Meyer, Nuala J.
    Reilly, John P.
    Anderson, Brian J.
    Palakshappa, Jessica A.
    Jones, Tiffanie K.
    Dunn, Thomas G.
    Shashaty, Michael G. S.
    Feng, Rui
    Christie, Jason D.
    Opal, Steven M.
    CRITICAL CARE MEDICINE, 2018, 46 (01) : 21 - 28
  • [2] Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
    Bresnihan, B
    Alvaro-Gracia, JM
    Cobby, M
    Doherty, M
    Domljan, Z
    Emery, P
    Nuki, G
    Pavelka, K
    Rau, R
    Rozman, B
    Watt, I
    Williams, B
    Aitchison, R
    McCabe, D
    Musikic, P
    ARTHRITIS AND RHEUMATISM, 1998, 41 (12): : 2196 - 2204
  • [4] COMPARATIVE RESPONSES OF HUMAN AND RABBIT INTERLEUKIN-1 INVIVO - EFFECT OF A RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST
    VONUEXKULL, C
    NOURSHARGH, S
    WILLIAMS, TJ
    IMMUNOLOGY, 1992, 77 (04) : 483 - 487
  • [5] INTERLEUKIN-1, INTERLEUKIN-1 RECEPTOR, AND INTERLEUKIN-1 RECEPTOR ANTAGONIST
    ESPAT, NJ
    ROGY, MA
    COPELAND, EM
    MOLDAWER, LL
    PROCEEDINGS OF THE NUTRITION SOCIETY, 1994, 53 (02) : 393 - 400
  • [6] INTERLEUKIN-1 RECEPTOR ANTAGONIST ACTIVITY OF A HUMAN INTERLEUKIN-1 INHIBITOR
    HANNUM, CH
    WILCOX, CJ
    AREND, WP
    JOSLIN, FG
    DRIPPS, DJ
    HEIMDAL, PL
    ARMES, LG
    SOMMER, A
    EISENBERG, SP
    THOMPSON, RC
    NATURE, 1990, 343 (6256) : 336 - 340
  • [7] The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
    Bresnihan, B
    BIODRUGS, 2001, 15 (02) : 87 - 97
  • [8] KIDNEY AS A MAJOR CLEARANCE ORGAN FOR RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST
    KIM, DC
    REITZ, B
    CARMICHAEL, DF
    BLOEDOW, DC
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (05) : 575 - 580
  • [9] INITIAL CRYSTALLOGRAPHIC ANALYSIS OF A RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN
    CLANCY, LL
    FINZEL, BC
    YEM, AW
    DEIBEL, MR
    STRAKALAITIS, NA
    BRUNNER, DP
    SWEET, RM
    EINSPAHR, HM
    ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 1994, 50 : 197 - 201
  • [10] The Prospect of Treating Rheumatoid Arthritis with Recombinant Human Interleukin-1 Receptor Antagonist
    Barry Bresnihan
    BioDrugs, 2001, 15 : 87 - 97